Hep C - adherence issues, page-2

Adherence issues need to be addressed by the consulting doctors. In the past patients have not been advised with enough conviction about the importance of adherence. This is changing..... any combination is going to have issues and the more pills or the longer the regime has to be taken will take its toll.

New treatments are coming but they are mainly combinations and will suffer the same fate in the compliance stakes.

HOWEVER:
Gilead's new Ledipasvir/Sovaldi single pill (once per day) will be FDA approved in THREE WEEKS.
It is just an eight week course for most patients and compliance will not be so much of an issue. As high as 99% cure rate! Relapsers and non responders will still have to take Ribavirin and extend the course out to twelve weeks.

Australian authorities IMO have been stalling approvals and are waiting for this latest combination to be US approved before making their move. IMO, there will be little demand for anything other than the new single pill combo until people can visit Uncle Benny's one stop shop sometime in 2018.
Gilead are curing about 14,000 people per month (this is blockbusting record breaking stuff) at present.......and it is only just keeping up the reinfection rate.

This means that even by 2018 the market will be still be huge for Benitec.